Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $10.00.

Several equities analysts recently weighed in on PYXS shares. Royal Bank of Canada lifted their target price on Pyxis Oncology from $7.00 to $10.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Stephens assumed coverage on Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective on the stock. William Blair lowered shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Finally, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, November 21st.

Insider Buying and Selling

In related news, CFO Pamela Ann Connealy acquired 88,850 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was acquired at an average price of $1.96 per share, with a total value of $174,146.00. Following the acquisition, the chief financial officer now directly owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. This trade represents a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 9.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PYXS. Fullcircle Wealth LLC purchased a new stake in shares of Pyxis Oncology during the 2nd quarter worth approximately $40,000. Intech Investment Management LLC bought a new stake in Pyxis Oncology in the third quarter worth $55,000. SG Americas Securities LLC purchased a new stake in Pyxis Oncology during the third quarter valued at $58,000. The Manufacturers Life Insurance Company purchased a new stake in Pyxis Oncology during the second quarter valued at $65,000. Finally, MetLife Investment Management LLC lifted its position in Pyxis Oncology by 41.1% during the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after purchasing an additional 5,484 shares during the last quarter. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Price Performance

Shares of PYXS stock opened at $1.52 on Friday. The company has a market cap of $90.39 million, a price-to-earnings ratio of -1.48 and a beta of 1.01. Pyxis Oncology has a 1 year low of $1.51 and a 1 year high of $6.85. The firm has a fifty day moving average price of $3.17 and a 200-day moving average price of $3.40.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.